A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
News Medical on MSN2h
Machine learning tool predicts cancer treatment response based on genetic mutationsA groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes-insights that could help doctors ...
Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...
According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...
Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
With 44,000 new diagnoses each year, non-small cell lung cancer is the second most frequent neoplasm in Italy after breast ...
We must come together to combat air pollution and move to clean energy to prevent more needless deaths from lung cancer.
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...
A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback